Ironwood Pharmaceuticals Gets FDA Approval Of Linzess For The Treatment Of Functional Constipation In Pediatric Patients 6 To 17 Years Of Age
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals has received FDA approval for Linzess, a treatment for functional constipation in pediatric patients aged 6 to 17 years.
June 12, 2023 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ironwood Pharmaceuticals' FDA approval of Linzess for pediatric patients may lead to increased revenue and market share.
The FDA approval of Linzess for pediatric patients expands Ironwood Pharmaceuticals' target market, potentially increasing revenue and market share. This positive news is likely to have a short-term positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100